James Korkola

Assistant Professor

Oregon Health & Science University

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

James Korkola is an Assistant Professor at Oregon Health and Science University in the United States. His research focuses on breast cancer, particularly in areas such as drug repositioning, the impact of the extracellular matrix on disease progression, and the molecular responses of cancer cells. He has published several articles that explore innovative approaches to cancer treatment and the molecular mechanisms underlying tumor behavior.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (9)

Gordon Mills

Oregon Health & Science University

UNITED STATES

View details

David Landreth Van Vactor, Jr.

Professor

Harvard Medical School

UNITED STATES

View details

Katherine Thompson-Peer

Assistant Professor

University of California, Irvine

UNITED STATES

View details

Malvina Papanastasiou

Broad Institute

UNITED STATES

View details

Gillian Hirst

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

Moqing Liu

Oregon Health & Science University

UNITED STATES

View details

Pepper Schedin

Professor

Oregon Health & Science University

UNITED STATES

View details

Jennifer Lopez

City of Hope

UNITED STATES

View details

Yunguan Wang

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Korkola

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Functional delineation of the luminal epithelial microenvironment in breast using cell-based screening in combinatorial microenvironments

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.

An altered extracellular matrix-integrin interface contributes to Huntington's disease-associated CNS dysfunction in glial and vascular cells.

A multi-omic analysis of MCF10A cells provides a resource for integrative assessment of ligand-mediated molecular and phenotypic responses.

INHBA is a mediator of aggressive tumor behavior in HER2+ basal breast cancer.

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

Systematic replication enables normalization of high-throughput imaging assays.

Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.

Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors

Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.

Collaborators (9)

Gordon Mills

David Landreth Van Vactor, Jr.

Katherine Thompson-Peer

Malvina Papanastasiou

Gillian Hirst

Moqing Liu

Pepper Schedin

Jennifer Lopez

Yunguan Wang

Make your next move.